BACKGROUND: Mycophenolic acid (MPA) exposure in pediatric patients with kidney transplant receiving body surface area (BSA)-based dosing exhibits large variability. Several genetic variants in glucuronosyltransferases (UGTs) and of multidrug resistance-associated protein 2 (MRP2) have independently been suggested to predict MPA exposure in adult patients with varying results. Here, the combined contribution of these genetic variants to MPA pharmacokinetic variability was investigated in pediatric renal transplant recipients who were on mycophenolic mofetil maintenance therapy. METHODS: MPA and MPA-glucuronide concentrations from 32 patients were quantified by high-performance liquid chromatography. MPA exposure (AUC) was estimated using a 4-point abbreviated sampling strategy (predose/trough and 20 minutes, 1 hour, and 3 hours after dose) using a validated pediatric Bayesian estimator. Genotyping was performed for all of the following single nucleotide polymorphisms (SNPs): UGT1A8 830G>A(*3), UGT1A9 98T>C(*3), UGT1A9-440C>T, UGT1A9-2152C>T, UGT1A9-275T>A, UGT2B7-900A>G, and MRP2-24T>C. RESULTS: Recipients heterozygous for MRP2-24T>C who also had UGT1A9-440C>T or UGT2B7-900A>G (n = 4), and MRP2-24T>C-negative recipients having both UGT1A9-440C>T and UGT2B7-900A>G (n = 5) showed a 2.2 and 1.7 times higher dose-dependent and BSA-normalized MPA-AUC compared with carriers of no or only 1 UGT-SNP (P < 0.001 and P = 0.01, respectively) (n = 7). Dose-dependent and BSA-normalized predose MPA concentrations were 3.0 and 2.4 times higher, respectively (P < 0.001). Interindividual variability in peak concentrations could be explained by the presence of the UGT1A9-440C>T genotype (P < 0.05). CONCLUSION: Our preliminary study demonstrates that combined UGT1A9-440C>T, UGT2B7-900A>G, and MRP2-24T>C polymorphisms can be important predictors of interindividual variability in MPA exposure in the pediatric population.
BACKGROUND:Mycophenolic acid (MPA) exposure in pediatric patients with kidney transplant receiving body surface area (BSA)-based dosing exhibits large variability. Several genetic variants in glucuronosyltransferases (UGTs) and of multidrug resistance-associated protein 2 (MRP2) have independently been suggested to predict MPA exposure in adult patients with varying results. Here, the combined contribution of these genetic variants to MPA pharmacokinetic variability was investigated in pediatric renal transplant recipients who were on mycophenolic mofetil maintenance therapy. METHODS:MPA and MPA-glucuronide concentrations from 32 patients were quantified by high-performance liquid chromatography. MPA exposure (AUC) was estimated using a 4-point abbreviated sampling strategy (predose/trough and 20 minutes, 1 hour, and 3 hours after dose) using a validated pediatric Bayesian estimator. Genotyping was performed for all of the following single nucleotide polymorphisms (SNPs): UGT1A8 830G>A(*3), UGT1A9 98T>C(*3), UGT1A9-440C>T, UGT1A9-2152C>T, UGT1A9-275T>A, UGT2B7-900A>G, and MRP2-24T>C. RESULTS: Recipients heterozygous for MRP2-24T>C who also had UGT1A9-440C>T or UGT2B7-900A>G (n = 4), and MRP2-24T>C-negative recipients having both UGT1A9-440C>T and UGT2B7-900A>G (n = 5) showed a 2.2 and 1.7 times higher dose-dependent and BSA-normalized MPA-AUC compared with carriers of no or only 1 UGT-SNP (P < 0.001 and P = 0.01, respectively) (n = 7). Dose-dependent and BSA-normalized predose MPA concentrations were 3.0 and 2.4 times higher, respectively (P < 0.001). Interindividual variability in peak concentrations could be explained by the presence of the UGT1A9-440C>T genotype (P < 0.05). CONCLUSION: Our preliminary study demonstrates that combined UGT1A9-440C>T, UGT2B7-900A>G, and MRP2-24T>C polymorphisms can be important predictors of interindividual variability in MPA exposure in the pediatric population.
Authors: Dennis A Hesselink; Reinier M van Hest; Ron A A Mathot; Fred Bonthuis; Willem Weimar; Ron W F de Bruin; Teun van Gelder Journal: Am J Transplant Date: 2005-05 Impact factor: 8.086
Authors: N Božina; Z Lalić; S Nađ-Škegro; A Borić-Bilušić; T Božina; Ž Kaštelan; V Trkulja Journal: Eur J Clin Pharmacol Date: 2017-06-18 Impact factor: 2.953
Authors: K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt Journal: Clin Pharmacol Ther Date: 2015-09 Impact factor: 6.875
Authors: Charles D Varnell; Tsuyoshi Fukuda; Cassie L Kirby; Lisa J Martin; Barry L Warshaw; Hiren P Patel; Deepa H Chand; Gina-Marie Barletta; Scott K Van Why; Rene G VanDeVoorde; Donald J Weaver; Amy Wilson; Priya S Verghese; Alexander A Vinks; Larry A Greenbaum; Jens Goebel; David K Hooper Journal: Pediatr Transplant Date: 2017-09-04
Authors: Justine Badée; Stephen Fowler; Saskia N de Wildt; Abby C Collier; Stephan Schmidt; Neil Parrott Journal: Clin Pharmacokinet Date: 2019-02 Impact factor: 6.447
Authors: Paola Krall; Dominique Yañez; Angélica Rojo; Ángela Delucchi; Miguel Córdova; Jorge Morales; Pía Boza; Alonso de la Rivera; Natalie Espinoza; Natalia Armijo; Luis E Castañeda; Mauricio J Farfán; Carolina Salas Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810